Objectives-The aim of this study was to assess the incidence of an aberrant right subclavian artery (ARSA) among an unselected population during second-trimester sonography and to review the importance of this conotruncal variant as a marker of Down syndrome.
T he most common benign abnormality of the aortic arch is an aberrant right subclavian artery (ARSA), also called arteria lusoria. 1 Although it may occur as an isolated abnormality, it can be associated with other congenital cardiac defects and chromosomal anomalies such as trisomy 21 and microdeletion of chromosome 22. The incidence of an ARSA in healthy populations is known to be about 1% to 2%, whereas its incidence in fetuses with Down syndrome has a wide range, varying between 8% in the first trimester and 28% to 37.5% in the second trimester. 2, 3 Although the strong relationship between Down syndrome and an ARSA has been implicated in preliminary studies, recent studies related to isolated cases of an ARSA have demonstrated less predictivity in detection of Down syndrome. 1, [4] [5] [6] [7] [8] [9] These findings necessitate further studies to clarify its importance in low-risk populations. From this standpoint, we aimed to assess the incidence of an ARSA in an unselected population and the importance of this conotruncal variant as a marker of Down syndrome.
Materials and Methods
This retrospective study was performed in a private clinic in Istanbul between March 2013 and March 2015.
All pregnant women who attended our antenatal clinic were offered detailed sonography in the second trimester, whether their a priori risks were high or low. Patients with advanced maternal age, abnormal first-trimester screening or second trimester biochemical test results, and maternal diseases such as diabetes were accepted as high risk. Women younger than 35 years and those with low risk on screening tests were accepted as low risk.
Women with singleton pregnancies who had the input qualifications were asked to participate in this research. This research was based on the principles of the Declaration of Helsinki. Detailed signed informed consent was obtained from each patient, and it was ensured that there was no loss or harm to the patients. Each patient was evaluated only once in the second trimester, and all examinations were performed by the same operator (I.H.K.). Examinations were performed transabdominally with high-frequency transducers (Voluson E8 Expert system, RAB6-D; GE Healthcare, Zipf, Austria). Visualization of an ARSA was attempted with the technique described by Chaoui et al. 1 The 3-vessel and trachea view was obtained. After identification of the junction of the aortic arch and ductal arch, the Doppler velocity was reduced to 15 to 30 cm/s. An ARSA was diagnosed as a separate vessel departing from this junction, running behind the trachea and anteriorly to the vertebra. Its arterial flow was also confirmed by pulsed Doppler imaging. The patients with an ARSA were offered invasive testing for karyotype analysis and fluorescence in situ hybridization for 22q11.2 microdeletion. For the patients who did not accept invasive testing prenatally, the karyotype was considered normal if the neonatal evaluation findings were normal. Neonates with a prenatally detected ARSA underwent fetal echocardiography, and all cases with an ARSA were verified postnatally. Only 1 of them (case 20), who was associated with severe multiple anomalies, was confirmed by autopsy after termination of the pregnancy.
Results
In 1913 second-trimester fetuses of unselected pregnant women, an ARSA was found in 20 patients (1.04%). The mean maternal age in our study population was 28.7 with 5.1 standard deviation (minimum age: 15, maximum age: 45 years), and the mean gestational week at diagnosis was 21.6 with 3.0 standard deviation (minimum: 14 weeks, maximum: 32 weeks). Demographic data for the 20 patients with an ARSA, their sonographic findings, and the results of their screening tests, karyotype analysis, and noninvasive prenatal tests are described in Table 1 .
Thirteen cases of an ARSA were isolated; no additional anomaly or finding that could be related to Down syndrome was detected in either the prenatal or postnatal period. These neonates did not have any problems during their neonatal periods. Seven cases were associated with other sonographic findings. Five cases were associated with soft markers, and 2 cases were associated with major anomalies. An intracardiac echogenic focus (n 5 3) was the most common associated finding. Other markers were a choroid plexus cyst in 1 case and pyelectasis in another. These nonisolated ARSA cases with soft markers were evaluated during the neonatal period, and no additional echocardiographic abnormality or any other system abnormality was detected. All neonates were examined postnatally, and no suspicious finding was detected, so they were accepted as chromosomally normal. Tetralogy of Fallot was the major anomaly seen in 2 cases. One of the cases with tetralogy of Fallot was also associated with a persistent left superior vena cava, a persistent right umbilical vein, hydrocephalus, rhombencephalosynapsis, and unilateral renal agenesis. Cordocentesis of this fetus revealed a normal karyotype. The patient opted to terminate the pregnancy, and autopsy confirmed the prenatal sonographic diagnosis. Prenatal karyotyping was not performed for the other fetus with tetralogy of Fallot, and the family continued the pregnancy. The prenatal diagnosis was confirmed by postnatal echocardiography. Although the postnatal peripheric karyotype of the neonate was normal, he died in the third postnatal month without having any operation.
Among 13 isolated cases of an ARSA, there were 3 patients with a high risk for aneuploidy and 7 with a low risk, and 3 had no screening test or any other risk factor. Within the 3 high-risk cases, although 1 had advanced maternal age and positive triple-test results, she refused invasive testing (case 1). The second high-risk case had only advanced maternal age (case 5). The third high-risk case had abnormal quadruple test results; she underwent amniocentesis, which revealed a normal karyotype (case 8). One of the low-risk patients preferred noninvasive prenatal testing (Harmony; Ariosa Diagnostics, San Jose, CA), and the results were reported as low risk for trisomy 21 (case 3). The rest of the low-risk patients refused noninvasive and invasive testing after receiving detailed information.
There were 7 ARSA cases with associated sonographic findings. Three of them were classified as high risk and 3 of them as low risk, and 1 case had no screening test. Three nonisolated ARSA cases had an intracardiac echogenic focus. One of them was at an advanced maternal age and did not accept invasive testing (case 14). Another nonisolated case had a choroid plexus cyst, advanced maternal age, and normal amniocentesis results (case 17). Another patient (case 18) who was associated with pyelectasis and advanced maternal age did not accept invasive testing (case 18). Although the remaining 2 nonisolated cases were lowrisk pregnancies, they were associated with a major cardiac anomaly (both had tetralogy of Fallot; cases 19 and 20). One patient in whom multiple anomalies were also detected underwent cordocentesis, the results of which were normal (case 20). The family opted for termination of the pregnancy because of multiple anomalies.
Only
In our study group, there were 2 fetuses with Down syndrome (0.1%), and neither of them had an ARSA. In 1 case of Down syndrome, multiple markers, such as an intracardiac echogenic focus, tetralogy of Fallot, and pyelectasis, were present, and the neonate was live born. The other fetus with Down syndrome had a thickened 
Discussion
This retrospective study aimed to find out the incidence of an ARSA in an unselected population during a second-trimester anomaly scan and to review the importance of this conotruncal variant as a marker of Down syndrome in an unselected population. The results of this study showed that the incidence of an ARSA was 1.04% in an unselected population. All of these cases were chromosomally normal. The ARSA was isolated in 13 of 20 fetuses; 5 fetuses were associated with minor abnormalities; and 2 of them were associated with tetralogy of Fallot ( Table 1) . The presence of an ARSA in fetuses with Down syndrome was described for the first time by Chaoui et al. 1 In their preliminary study, they identified an ARSA in 35.7% of fetuses with Down syndrome in the second and third trimester (5 of 14). Since then, several studies reported that an ARSA was one of the most powerful independent markers of Down syndrome. 4, 10 However, in most of these studies, the populations were composed of high-risk pregnancies with a higher incidence of Down syndrome than the expected incidence. The risk of Down syndrome for a woman aged 35 years is known as 1 per 250 in the second trimester and 1 per 385 at term. 11 Paladini and Volpe 12 reported the incidence of Down syndrome in a population at 20 weeks' gestation as 1 per 500. In a meta-analysis, Agathokleous et al 10 reported that an ARSA increased the Down syndrome risk about 3-to 4-fold and also emphasized that most of the studies included in their meta-analysis were performed in high-risk pregnancies. Borenstein et al 3 found that the incidence of an ARSA among high-risk pregnancies was 29%, with a 1.04% incidence of Down syndrome. Paladini et al 4 studied the largest Down syndrome population and found that the incidence of an ARSA was 25%. Borenstein et al 3 and Paladini et al 4 reported that an ARSA increased the Down syndrome risk about 16-to 20-fold. Later, Yazicioglu et al 7 studied the prevalence of an ARSA in a mixed population and found a prevalence rate of 1.1%. However, the study was considered to be composed of high-risk pregnancies, owing to the high incidence of Down syndrome (0.9%) in their study population (20 of 2081). Unlike other studies, the prevalence of Down syndrome in our study group was found to be 0.1%, which was lower than expected, reflecting that, obviously, our population was composed of mostly low-risk patients.
In recent studies, no cases of Down syndrome were reported in fetuses with an isolated ARSA. [5] [6] [7] [8] [9] These 5 studies reported that all Down syndrome cases with an ARSA were associated with other markers. A study in a low-risk population by Zalel et al 5 found that the prevalence of an ARSA was 1.4%. In addition to this low-risk population, they evaluated 8 Down syndrome cases separately, which were referred to them with known karyotypes or suspicious sonographic findings. In 3 of 8 Down syndrome cases, they detected an ARSA, and all 3 also had additional sonographic findings. They reported the frequency of an ARSA in Down syndrome cases (37.5%) separately from their low-risk population. Willruth et al 6 reported 1 case of Down syndrome with an ARSA in 14 ARSA cases among 1337 mixedrisk second-trimester fetuses. Yazicioglu et al 7 studied the prevalence of an ARSA in a mixed population and found it to be 1.1%. The incidence of Down syndrome in their population was 0.9% (20 of 2081), which was higher than expected in a healthy population. Therefore, their high Down syndrome incidence made us think that their study group consisted of mostly high-risk patients. De Le on-Luis et al 8 screened the largest unselected population to date and found 60 ARSA cases among 8781 fetuses, for a prevalence rate of 0.7%. Seven of the 60 cases had Down syndrome, and all were associated with the most powerful markers of Down syndrome, such as nasal bone hypoplasia, a thickened nuchal fold, cystic hygroma, and ventriculomegaly, which were also indications for karyotype analysis. They reported the sensitivity and specificity of an ARSA for Down syndrome to be 31.8% and 99.3%, respectively. They also reported a positive likelihood ratio for an isolated ARSA as 0, and for a nonisolated ARSA, it was 199. Similar to our results, they did not find any correlation between an isolated ARSA and Down syndrome.
In the last systematic review and meta-analysis evaluating an ARSA in fetuses with Down syndrome, Scala et al 9 found the prevalence of an ARSA in fetuses with Down syndrome to be 3.6%, and in euploid fetuses, it was found to be 1.02%. Although this meta-analysis revealed that an ARSA is clinically an important marker of Down syndrome, it was not found to be sufficient to recommend fetal karyotyping in isolated cases.
Our study had 2 limitations. First, some of the pregnancy outcomes are unfortunately unknown because of the lack of postnatal follow-up. Second, we performed postnatal echocardiography only on fetuses with a prenatal diagnosis of an ARSA. We did not perform postnatal echocardiography on every neonate. Although an ARSA was found to have a close relationship with structural and chromosomal anomalies in previous studies, our study found a weak association with Down syndrome in a low-risk population, similar to recent studies. It is evident that an ARSA is more commonly detected in fetuses with Down syndrome than euploid fetuses, and in most cases, it is associated with other pathologic sonographic findings.
The evaluation of the presence or absence of an ARSA is a part of fetal echocardiography. If an ARSA is detected during a sonographic examination, the fetus should be handled more carefully, with a search for additional sonographic findings. In the presence of additional findings, patients should be offered invasive diagnostic procedures, whereas in isolated cases, a highly accurate noninvasive technique (cell-free DNA) may be suggested.
In conclusion, this study showed that the detection of an ARSA is not a strong marker of Down syndrome as much as nasal bone hypoplasia, a thickened nuchal fold, and ventriculomegaly. An ARSA by itself does not create a sufficient indication for invasive testing. Further studies are warranted in larger groups of patients to show the importance of this finding in unselected pregnancies.
